Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones. 1992

B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, New York 12144.

Two series of medorinone (3) analogs were prepared by modifications at C(2) and C(5). The C(2)-series was prepared from 2-chloro-5-methyl-1,6-naphthyridine (4) by replacement of the chloro group with various nucleophiles. The C(5)-series was prepared from 5-acyl-6-[2-(dimethylamino)-ethenyl]-2(1H)-pyridinone (11), 5-bromo-1,6-naphthyridin-2(1H)-one (17), and 1,3-diketones 19 and 27. 1,6-Naphthyridin-2(1H)-ones are novel inhibitors of cAMP PDE III. Modification of the carbonyl group of 3 or N-methylation at N(1) resulted in a dramatic loss of enzyme activity. Absence of the C(5)-methyl group of medorinone (3) or its shift to C(3) or C(7) also resulted in reduced activity. Substitution at C(3) also diminished activity. However, substitution at C(5) by a wide variety of substituents led to improvement of enzyme activity and several C(5)-substituted analogs were more potent than milrinone.

UI MeSH Term Description Entries
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015105 3',5'-Cyclic-AMP Phosphodiesterases Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. 3',5'-Cyclic AMP 5'-Nucleotidohydrolase,3',5'-Cyclic-Nucleotide Phosphodiesterase,CAMP Phosphodiesterase,3',5' Cyclic AMP Phosphodiesterase,3',5'-Cyclic AMP Phosphodiesterase,3',5'-Cyclic Nucleotide Phosphodiesterase,3',5'-Cyclic-AMP Phosphodiesterase,3',5'-Nucleotide Phosphodiesterase,3,5-Cyclic AMP 5-Nucleotidohydrolase,3,5-Cyclic AMP Phosphodiesterase,3',5' Cyclic AMP 5' Nucleotidohydrolase,3',5' Cyclic AMP Phosphodiesterases,3',5' Cyclic Nucleotide Phosphodiesterase,3',5' Nucleotide Phosphodiesterase,3,5 Cyclic AMP 5 Nucleotidohydrolase,3,5 Cyclic AMP Phosphodiesterase,5'-Nucleotidohydrolase, 3',5'-Cyclic AMP,5-Nucleotidohydrolase, 3,5-Cyclic AMP,AMP 5'-Nucleotidohydrolase, 3',5'-Cyclic,AMP 5-Nucleotidohydrolase, 3,5-Cyclic,AMP Phosphodiesterase, 3',5'-Cyclic,AMP Phosphodiesterase, 3,5-Cyclic,Nucleotide Phosphodiesterase, 3',5'-Cyclic,Phosphodiesterase, 3',5'-Cyclic AMP,Phosphodiesterase, 3',5'-Cyclic Nucleotide,Phosphodiesterase, 3',5'-Cyclic-AMP,Phosphodiesterase, 3',5'-Cyclic-Nucleotide,Phosphodiesterase, 3',5'-Nucleotide,Phosphodiesterase, 3,5-Cyclic AMP,Phosphodiesterase, CAMP,Phosphodiesterases, 3',5'-Cyclic-AMP

Related Publications

B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
October 2021, Pharmaceuticals (Basel, Switzerland),
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
August 2016, European journal of medicinal chemistry,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
April 1994, Biological & pharmaceutical bulletin,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
August 2000, Journal of medicinal chemistry,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
February 2014, Bioorganic & medicinal chemistry letters,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
November 1988, Journal of medicinal chemistry,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
March 1979, Journal of medicinal chemistry,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
April 2023, Organic & biomolecular chemistry,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
June 2022, Journal of medicinal chemistry,
B Singh, and G Y Lesher, and K C Pluncket, and E D Pagani, and D C Bode, and R G Bentley, and M J Connell, and L T Hamel, and P J Silver
December 2017, ACS combinatorial science,
Copied contents to your clipboard!